Simulations Plus, Inc. (SLP)

Market Cap	936.49M
Revenue (ttm)	64.67M
Net Income (ttm)	10.52M
Shares Out	19.98M
EPS (ttm)	0.53
PE Ratio	88.42
Forward PE	83.35
Dividend	$0.24 (0.51%)
Ex-Dividend Date	Apr 26, 2024

Volume	258,583
Open	46.29
Previous Close	46.18
Day's Range	45.89 - 47.91
52-Week Range	32.69 - 52.69
Beta	0.75
Analysts	Strong Buy
Price Target	60.50 (+29.11%)
Earnings Date	Jul 2, 2024

About SLP

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Jun 18, 1997
• Employees: 192
• Stock Exchange: NASDAQ
• Ticker Symbol: SLP

Financial Performance

In 2023, SLP's revenue was $59.58 million, an increase of 10.52% compared to the previous year's $53.91 million. Earnings were $9.96 million, a decrease of -20.20%.

Analyst Forecast

According to 3 analysts, the average rating for SLP stock is "Strong Buy." The 12-month stock price forecast is $60.5, which is an increase of 29.11% from the latest price.

Price Target

$60.5

(29.11% upside)

Analyst Consensus: Strong Buy